BioBridgeX
Log inCompare quotes
Modality

Gene Therapy (AAV / Viral Vector) CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing gene therapy (AAV or viral vector) means buying specialist help across vector design, preclinical and IND-enabling studies, and the hard part: GMP viral vector and plasmid DNA manufacturing with potency, infectivity, and empty-versus-full capsid analytics. On BioBridgeX, buyers source and compare qualified CROs and CDMOs in one place, free for buyers, with BioBridgeX as the neutral marketplace.

Gene Therapy (AAV / Viral Vector) CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Gene Therapy (AAV / Viral Vector) CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture a Gene Therapy (AAV / Viral Vector) drug?

Gene therapy stretches a development team across two very different worlds. The early science looks like any biologics program: pick a transgene, choose or engineer a capsid serotype that reaches the target tissue, design the expression cassette and promoter, then prove in preclinical models that the construct does what you claim without lighting up the immune system. The hard, expensive reality lands later, in CMC. The vector you make is not a small molecule with a clean structure; it is a population of viral particles, some full of your genome and some empty, and your process and your analytics define the product as much as the sequence does. That is why so many gene therapy programs that read well on biology stall at manufacturing.

A typical program needs a CRO for the discovery and preclinical work (capsid screening, biodistribution and shedding studies, immunogenicity and GLP toxicology in a relevant species), then a CDMO for process development and GMP supply. The manufacturing side is where the specialist gap is widest. Upstream, you are running either a transient transfection process (three or four plasmids into HEK293 cells, which means you also need GMP plasmid DNA) or a producer or packaging cell line. Downstream, you are clarifying, concentrating, and polishing with affinity chromatography and tangential flow filtration, then trying to separate full capsids from empty ones, often by anion exchange or gradient ultracentrifugation. Each step bleeds yield, and AAV yields are low to begin with, so process choices made early ripple straight into cost of goods and how many patients a batch can dose.

The analytics are the part generalists underestimate. You need vector genome titer (qPCR or ddPCR), capsid titer, the full-to-empty ratio, infectivity and potency assays that tie back to mechanism, residual host cell DNA and protein, residual plasmid and helper, replication-competent virus testing, and aggregation. A CDMO that has built and qualified these assays for AAV, and ideally has a platform process across serotypes, is in a different category from a contract biologics shop that lists gene therapy on a capabilities page. Specialist viral vector CDMOs differ from generalists in three concrete ways: a real platform process they can adapt rather than invent from scratch, a qualified AAV-specific analytical panel, and people who have actually carried a vector through a regulatory filing and the FDA potency and comparability questions that come with it.

How do you choose a CRO or CDMO for Gene Therapy (AAV / Viral Vector)?

The instinct to chase the biggest name is usually wrong here, because capacity in this field is genuinely scarce and a marquee CDMO booked solid for eighteen months can be worse for your program than a focused vector house with an open suite. Anchor the decision on demonstrated AAV experience with your serotype and your scale, not a logo or a glossy capabilities deck. Score two or three suppliers against the same written scope, and weight the manufacturing and analytics evidence heavily, since that is where gene therapy programs actually fail.

Use the checklist below when you compare suppliers. Treat anything a supplier cannot answer with specifics as a flag, not a detail to sort out later.

  • Relevant platform and track record: ask which AAV serotypes they have produced, whether they run a transient transfection or stable producer cell line process, and how many client vectors have reached IND or BLA. A reusable platform process beats a bespoke one invented for your project.
  • GxP and analytical capability for this modality: confirm GMP suites at the right grade, a qualified AAV analytics panel (vector genome titer, full-to-empty ratio, infectivity and potency, residual host cell DNA and protein, replication-competent virus), and whether potency and identity assays are developed in-house or outsourced.
  • Plasmid and raw material supply: AAV needs GMP plasmid DNA, and plasmid lead times can dominate your timeline. Check whether the CDMO makes plasmid in-house or relies on a third party, and whether helper and packaging components are secured.
  • Capacity and scale: get real suite availability and a realistic slot, the bioreactor scale they can deliver (from 50L suspension up to 200L or 500L and beyond), and an honest read on yield per batch at your serotype, since that decides how many patients a lot can dose.
  • Regulatory experience: confirm they have supported INDs and ideally a BLA, can produce a potency and comparability story the FDA or EMA will accept, and have lived through real agency questions on empty capsids, RCV, and process changes.
  • IP and confidentiality: settle ownership of process and analytical know-how and any platform-derived improvements in writing, watch for proprietary cell lines or capsids that carry royalty or freedom-to-operate strings, and get a CDA in place before disclosing your construct.

Frequently asked questions

What is the difference between a gene therapy CRO and a viral vector CDMO?
They cover different halves of the program. A CRO runs the research and preclinical work: capsid and serotype screening, transgene and cassette design, biodistribution and shedding studies, immunogenicity, and GLP toxicology that supports your IND. A CDMO makes the actual drug, which for AAV means process development plus GMP manufacturing of the viral vector and usually the plasmid DNA that feeds it, along with the analytics that release each batch. Some larger organizations do both, but the manufacturing and analytical depth is where you should scrutinize hardest, because that is where gene therapy programs stall. On BioBridgeX you can source both sides and contract directly with each chosen supplier in one place.
How much does AAV gene therapy manufacturing cost and how long does it take?
It is expensive and slow relative to most modalities, and any single number is misleading because it swings with serotype, scale, and yield. The honest framing: GMP plasmid DNA and AAV process development plus a GMP campaign typically run many months to over a year before you have releasable material, and plasmid lead times alone can be a meaningful chunk of that. Cost is driven by low AAV yields, the number of plasmids in a transfection process, and the long analytical release panel. The practical levers are choosing a CDMO with a platform process rather than a bespoke one, locking plasmid supply early, and scoping process development, engineering runs, and GMP lots as separate milestones with go/no-go gates.
Why does the full-to-empty capsid ratio matter when choosing a CDMO?
Empty capsids carry no transgene but still trigger an immune response and dilute your effective dose, so regulators and clinicians care about the ratio, and your CDMO's ability to measure and control it is a core competence, not a nicety. Separating full from empty capsids is one of the hardest downstream steps, usually done by anion exchange chromatography or gradient ultracentrifugation, and each approach trades purity against yield. When you evaluate a CDMO, ask how they measure the full-to-empty ratio (analytical ultracentrifugation, charge-detection mass spec, ddPCR-to-ELISA ratio), what ratio they routinely achieve at your serotype, and how they control it at scale. A supplier that is vague here has not solved the problem.
Should I use a transient transfection process or a stable producer cell line?
Most AAV today is made by transient transfection, where three or four plasmids go into HEK293 cells. It is flexible and fast to start, which suits early programs, but it consumes large amounts of GMP plasmid and gets expensive and harder to control as you scale. Stable producer or packaging cell lines remove the plasmid burden and can improve consistency and cost at commercial scale, but they take time and money to build and lock you into a serotype and construct. The right answer depends on where you are: transient is often pragmatic through early clinical, while a stable line becomes attractive if you are heading toward a large indication. Ask each CDMO which they run, and whether they can carry you from one to the other without a full comparability restart.
Do I need a CDMO with prior FDA or EMA gene therapy filing experience?
Yes, and it is one of the most undervalued selection criteria. Gene therapy CMC draws specific agency scrutiny: potency assays that genuinely reflect mechanism, comparability when you change process or scale, replication-competent virus testing, and control of empty capsids and residual impurities. A CDMO that has carried a vector through an IND, and ideally a BLA, has already answered these questions and built the documentation and assays to support them. One that has only made research-grade material will be learning on your program, on your timeline and budget. Ask directly how many client vectors have reached IND or approval, and whether their potency and comparability strategy has survived real agency review.
Can BioBridgeX handle a program that needs both a preclinical CRO and a viral vector CDMO?
Yes, that is a core reason buyers use it. You can source the preclinical CRO and the viral vector CDMO (and the GMP plasmid DNA supplier, if separate) through the same platform, comparing quotes and contracting directly with each chosen supplier in one place, with BioBridgeX as the neutral marketplace across all of them. It is free for buyers, with a flat 2% fee charged to suppliers, and it spans all indications and modalities, so a gene therapy program that also needs, say, analytical method development or fill-finish does not splinter into a dozen separate contracts. You start the sourcing yourself and compare qualified suppliers before committing.

Source Gene Therapy (AAV / Viral Vector) work with one contract

Compare transparent quotes from qualified Gene Therapy (AAV / Viral Vector) CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes